PubRank

Vinata B Lokeshwar

Author PubWeight™ 35.28‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol 2009 2.36
2 Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007 2.12
3 Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 2003 1.82
4 HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 2009 1.72
5 Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 2008 1.48
6 Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005 1.48
7 Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004 1.34
8 Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 2008 1.24
9 Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 2003 1.22
10 Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2010 1.18
11 Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006 1.17
12 Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 2011 1.15
13 Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 2008 1.13
14 Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int 2014 1.12
15 Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007 1.08
16 Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 2004 1.05
17 Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 2009 1.03
18 Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 2003 0.99
19 HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer 2007 0.95
20 Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol 2012 0.94
21 C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer 2012 0.93
22 Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer 2011 0.88
23 Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Cancer Biomark 2011 0.85
24 Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther 2008 0.83
25 Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck 2011 0.81
26 Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol 2012 0.80
27 An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. Cancer Chemother Pharmacol 2003 0.78
28 Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases. Glycobiology 2005 0.78
29 Age--an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades. World J Urol 2013 0.77
30 Are there molecular signatures for predicting bladder cancer prognosis? J Urol 2006 0.76
31 Re: Urine based markers of urological malignancy. J Urol 2002 0.75